News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Phagenesis Ltd Wins Bionow Award for Healthcare Project of the Year 2012


12/3/2012 3:12:03 PM

Manchester, UK – 3 December 2012 – Phagenesis Ltd, the global leader in the treatment of dysphagia, has won the Bionow Healthcare Project of the Year 2012 award. The award follows the launch of its first product, Phagenyx™, a medical device that treats dysphagia (difficulty swallowing) after stroke, in October.

Around half of stroke patients suffer with dysphagia1, a condition that is usually managed with puréed diet and tube feeding.

The award was sponsored by TRUSTECH, the North West NHS Innovation Service and entrants were judged on the impact of the product on the clinical problem it addresses, the quality of the product and the degree of innovation. The award was highly contested but on presenting the award Dr. Richard Deed, Innovation Unit Manager of TRUSTECH, said the judge’s decision was unanimous.

The award was collected by Dr Conor Mulrooney, Chief Operating Officer and Co-founder, at Phagenesis.

Daniel Green, CEO of Phagenesis, said: "The team at Phagenesis has made such enormous progress in the past year and thoroughly deserves the recognition that this award represents. Our task now is to put Phagenyx to work helping patients. Dysphagia is a blight on the lives of millions of people around the world, and is a true unmet medical need."

The annual awards dinner was attended by more than 280 executives from the biomedical sector.

Geoff Davison, CEO of Bionow, said: ‘The winners represent the cream of one of the leading clusters of biomedical businesses in the UK.”

[1] *http://stroke.ahajournals.org/content/36/12/2756.short

About Phagenesis

Phagenesis is developing the first clinically proven treatment for dysphagia, a debilitating and often lethal condition in which the patient’s ability to swallow is damaged. Dysphagia can lead to the inhalation of solids or liquids followed by pneumonia. Sufferers may face being fed through a tube indefinitely, reduced life expectancy, and many are treated for depression. Phagenesis raised a £2 million Series A financing in 2010 and a €7m financing in 2011. For more information, please visit our website at www.phagenesis.com.

About Bionow

Bionow is a specialist business development and services company focused on the biomedical industry in the North of England and has over 160 members.

Press contact:

Daniel Green

daniel.green@phagenesis.com

+44 (0)161 820 4525

+44(0)161 820 4524

+44 (0)7968 183 512


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES